MicroRNAs in Parkinson's disease

Neurobiology of Disease

Volumn 46, Issue 2, 2012, Pages 279-284

  Mouradian, M Maral ^a  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

synuclein; Dopamine; Gene regulation; Genetic; LRRK2; MicroRNA; MRNA translation; Neurodegeneration; Neuron; Parkinson; Polymorphism

Indexed keywords

ALPHA SYNUCLEIN; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 20; MICRORNA; MICRORNA 124; MICRORNA 130; MICRORNA 142; MICRORNA 153; MICRORNA 204; MICRORNA 433; MICRORNA 7; MICRORNA 98; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; BIOACCUMULATION; CELLULAR DISTRIBUTION; GENE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE LOCATION; GENE REGULATORY NETWORK; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; LRRK2 GENE; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW;

ALPHA-SYNUCLEIN; ANIMALS; BRAIN; DOPAMINERGIC NEURONS; HUMANS; MICRORNAS; NERVE NET; PARKINSON DISEASE;

EID: 84859500773     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2011.12.046     Document Type: Review

References (85)

1. Ambros V., et al. MicroRNAs and other tiny endogenous RNAs in C. elegans. Curr. Biol. 2003, 13:807-818.
2. Asikainen S., et al. Global microRNA expression profiling of Caenorhabditis elegans Parkinson's disease models. J. Mol. Neurosci. 2010, 41:210-218.
3. Bak M., et al. MicroRNA expression in the adult mouse central nervous system. RNA 2008, 14:432-444.
4. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
5. Beyer K., et al. Alpha- and beta-synuclein expression in Parkinson disease with and without dementia. J. Neurol. Sci. 2011, 310:112-117.
6. Bisaglia M., et al. Alpha-synuclein overexpression increases dopamine toxicity in BE2-M17 cells. BMC Neurosci. 2010, 11:41.
7. Chartier-Harlin M.C., et al. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 2004, 364:1167-1169.
8. Cheng A.M., et al. Antisense inhibition of human miRNAs and indications for an involvement of miRNA in cell growth and apoptosis. Nucleic Acids Res. 2005, 33:1290-1297.
9. Chiba-Falek O., Nussbaum R.L. Effect of allelic variation at the NACP-Rep1 repeat upstream of the alpha-synuclein gene (SNCA) on transcription in a cell culture luciferase reporter system. Hum. Mol. Genet. 2001, 10:3101-3109.
10. Chiba-Falek O., et al. Levels of alpha-synuclein mRNA in sporadic Parkinson disease patients. Mov. Disord. 2006, 21:1703-1708.
11. Cronin K.D., et al. Expansion of the Parkinson disease-associated SNCA-Rep1 allele upregulates human alpha-synuclein in transgenic mouse brain. Hum. Mol. Genet. 2009, 18:3274-3285.
12. Cuervo A.M., et al. Protein degradation, aggregation, and misfolding. Mov. Disord. 2010, 25(Suppl. 1):S49-S54.
13. Cullen V., et al. Acid beta-glucosidase mutants linked to gaucher disease, parkinson disease, and lewy body dementia alter alpha-synuclein processing. Ann. Neurol. 2011, 69:940-953.
14. Dachsel J.C., et al. The ups and downs of alpha-synuclein mRNA expression. Mov. Disord. 2007, 22:293-295.
15. Davis E., et al. RNAi-mediated allelic trans-interaction at the imprinted Rtl1/Peg11 locus. Curr. Biol. 2005, 15:743-749.
16. de Mena L., et al. FGF20 rs12720208 SNP and microRNA-433 variation: no association with Parkinson's disease in Spanish patients. Neurosci. Lett. 2010, 479:22-25.
17. de Mena L., et al. Analysis of the Micro-RNA-133 and PITX3 genes in Parkinson's disease. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2010, 153B:1234-1239.
18. Doxakis E. Post-transcriptional regulation of alpha-synuclein expression by mir-7 and mir-153. J. Biol. Chem. 2010, 285:12726-12734.
19. Farh K.K., et al. The widespread impact of mammalian MicroRNAs on mRNA repression and evolution. Science 2005, 310:1817-1821.
20. Farrer M., et al. alpha-Synuclein gene haplotypes are associated with Parkinson's disease. Hum. Mol. Genet. 2001, 10:1847-1851.
21. Farrer M., et al. Comparison of kindreds with parkinsonism and alpha-synuclein genomic multiplications. Ann. Neurol. 2004, 55:174-179.
22. Feany M.B., Bender W.W. A Drosophila model of Parkinson's disease. Nature 2000, 404:394-398.
23. Fukagawa T., et al. Dicer is essential for formation of the heterochromatin structure in vertebrate cells. Nat. Cell Biol. 2004, 6:784-791.
24. Gehrke S., et al. Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression. Nature 2010, 466:637-641.
25. Girling R., et al. A new component of the transcription factor DRTF1/E2F. Nature 1993, 362:83-87.
26. Grundemann J., et al. Elevated alpha-synuclein mRNA levels in individual UV-laser-microdissected dopaminergic substantia nigra neurons in idiopathic Parkinson's disease. Nucleic Acids Res. 2008, 36:e38.
27. Hamza T.H., et al. Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nat. Genet. 2010, 42:781-785.
28. Hebert S.S., De Strooper B. Molecular biology. miRNAs in neurodegeneration. Science 2007, 317:1179-1180.
29. Hwang D.Y., et al. Selective loss of dopaminergic neurons in the substantia nigra of Pitx3-deficient aphakia mice. Brain Res. Mol. Brain Res. 2003, 114:123-131.
30. Ibanez P., et al. Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet 2004, 364:1169-1171.
31. Imai Y., et al. Phosphorylation of 4E-BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila. EMBO J. 2008, 27:2432-2443.
32. Jegga A.G., et al. Systems biology of the autophagy-lysosomal pathway. Autophagy 2011, 7:477-489.
33. Jiang H., et al. Parkinson's disease genetic mutations increase cell susceptibility to stress: mutant alpha-synuclein enhances H2O2- and Sin-1-induced cell death. Neurobiol. Aging 2007, 28:1709-1717.
34. Junn E., Mouradian M.M. Human alpha-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine. Neurosci. Lett. 2002, 320:146-150.
35. Junn E., et al. Repression of alpha-synuclein expression and toxicity by microRNA-7. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:13052-13057.
36. Kanda S., et al. Enhanced vulnerability to oxidative stress by alpha-synuclein mutations and C-terminal truncation. Neuroscience 2000, 97:279-284.
37. Kefas B., et al. MicroRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res. 2008, 68:3566-3572.
38. Kim J., et al. A microRNA feedback circuit in midbrain dopamine neurons. Science 2007, 317:1220-1224.
39. Kingsbury A.E., et al. Alteration in alpha-synuclein mRNA expression in Parkinson's disease. Mov. Disord. 2004, 19:162-170.
40. Kumar A., et al. The Parkinson's disease associated LRRK2 exhibits weaker in vitro phosphorylation of 4E-BP compared to autophosphorylation. PLoS One 2010, 5:e8730.
41. Lakso M., et al. Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human alpha-synuclein. J. Neurochem. 2003, 86:165-172.
42. Lee R.C., Ambros V. An extensive class of small RNAs in Caenorhabditis elegans. Science 2001, 294:862-864.
43. Linnertz C., et al. Genetic regulation of alpha-synuclein mRNA expression in various human brain tissues. PLoS One 2009, 4:e7480.
44. Maraganore D.M., et al. Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease. JAMA 2006, 296:661-670.
45. Martinat C., et al. Cooperative transcription activation by Nurr1 and Pitx3 induces embryonic stem cell maturation to the midbrain dopamine neuron phenotype. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:2874-2879.
46. Masliah E., et al. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 2000, 287:1265-1269.
47. Masliah E., et al. Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron 2005, 46:857-868.
48. Masliah E., et al. Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease. PLoS One 2011, 6:e19338.
49. Mazzulli J.R., et al. Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 2011, 146(1):37-52.
50. Minones-Moyano E., et al. MicroRNA profiling of Parkinson's disease brains identifies early downregulation of miR-34b/c which modulate mitochondrial function. Hum. Mol. Genet. 2011, 20:3067-3078.
51. Mizuta I., et al. Multiple candidate gene analysis identifies alpha-synuclein as a susceptibility gene for sporadic Parkinson's disease. Hum. Mol. Genet. 2006, 15:1151-1158.
52. Mueller J.C., et al. Multiple regions of alpha-synuclein are associated with Parkinson's disease. Ann. Neurol. 2005, 57:535-541.
53. Mutez E., et al. SNCA locus duplication carriers: from genetics to Parkinson disease phenotypes. Hum. Mutat. 2011, 32:E2079-E2090.
54. Myhre R., et al. Multiple alpha-synuclein gene polymorphisms are associated with Parkinson's disease in a Norwegian population. Acta Neurol. Scand. 2008, 118:320-327.
55. Nichols W.C., et al. Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset. Neurology 2009, 72:310-316.
56. Nishioka K., et al. Expanding the clinical phenotype of SNCA duplication carriers. Mov. Disord. 2009, 24:1811-1819.
57. Nunes I., et al. Pitx3 is required for development of substantia nigra dopaminergic neurons. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:4245-4250.
58. Ohmachi S., et al. FGF-20, a novel neurotrophic factor, preferentially expressed in the substantia nigra pars compacta of rat brain. Biochem. Biophys. Res. Commun. 2000, 277:355-360.
59. Ohmachi S., et al. Preferential neurotrophic activity of fibroblast growth factor-20 for dopaminergic neurons through fibroblast growth factor receptor-1c. J. Neurosci. Res. 2003, 72:436-443.
60. Paisan-Ruiz C., et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004, 44:595-600.
61. Pals P., et al. alpha-Synuclein promoter confers susceptibility to Parkinson's disease. Ann. Neurol. 2004, 56:591-595.
62. Petrucelli L., et al. Parkin protects against the toxicity associated with mutant alpha-synuclein: proteasome dysfunction selectively affects catecholaminergic neurons. Neuron 2002, 36:1007-1019.
63. Pietersen C.Y., et al. Obtaining high quality RNA from single cell populations in human postmortem brain tissue. J. Vis. Exp. 2009, 30:1444.
64. Pietersen C.Y., et al. Neuronal type-specific gene expression profiling and laser-capture microdissection. Methods Mol. Biol. 2011, 755:327-343.
65. Rockenstein E., et al. Altered expression of the synuclein family mRNA in Lewy body and Alzheimer's disease. Brain Res. 2001, 914:48-56.
66. Ross O.A., et al. Familial genes in sporadic disease: common variants of alpha-synuclein gene associate with Parkinson's disease. Mech. Ageing Dev. 2007, 128:378-382.
67. Sekine T., et al. Clinical course of the first Asian family with Parkinsonism related to SNCA triplication. Mov. Disord. 2010, 25:2871-2875.
68. Sethi P., Lukiw W.J. Micro-RNA abundance and stability in human brain: specific alterations in Alzheimer's disease temporal lobe neocortex. Neurosci. Lett. 2009, 459:100-104.
69. Sidransky E., et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N. Engl. J. Med. 2009, 361:1651-1661.
70. Simon-Sanchez J., et al. Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nat. Genet. 2009, 41:1308-1312.
71. Singleton A.B., et al. alpha-Synuclein locus triplication causes Parkinson's disease. Science 2003, 302:841.
72. Smith W.W., et al. Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat. Neurosci. 2006, 9:1231-1233.
73. Sotiriou S., et al. A single nucleotide polymorphism in the 3'UTR of the SNCA gene encoding alpha-synuclein is a new potential susceptibility locus for Parkinson disease. Neurosci. Lett. 2009, 461:196-201.
74. Spillantini M.G., Goedert M. The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Ann. N. Y. Acad. Sci. 2000, 920:16-27.
75. Spillantini M.G., et al. Alpha-synuclein in lewy bodies. Nature 1997, 388:839-840.
76. Stefanis L., et al. Expression of A53T mutant but not wild-type alpha-synuclein in PC12 cells induces alterations of the ubiquitin-dependent degradation system, loss of dopamine release, and autophagic cell death. J. Neurosci. 2001, 21:9549-9560.
77. Tam O.H., et al. Pseudogene-derived small interfering RNAs regulate gene expression in mouse oocytes. Nature 2008, 453:534-538.
78. Tong J., et al. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation. Brain 2010, 133:172-188.
79. van der Walt J.M., et al. Fibroblast growth factor 20 polymorphisms and haplotypes strongly influence risk of Parkinson disease. Am. J. Hum. Genet. 2004, 74:1121-1127.
80. Vila M., et al. Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP. J. Neurochem. 2000, 74:721-729.
81. Wang G., et al. Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein. Am. J. Hum. Genet. 2008, 82:283-289.
82. Wider C., et al. FGF20 and Parkinson's disease: no evidence of association or pathogenicity via alpha-synuclein expression. Mov. Disord. 2009, 24:455-459.
83. Wienholds E., et al. MicroRNA expression in zebrafish embryonic development. Science 2005, 309:310-311.
84. Winkler S., et al. alpha-Synuclein and Parkinson disease susceptibility. Neurology 2007, 69:1745-1750.
85. Zimprich A., et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004, 44:601-607.